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We report 11 cases of severe Plasmodium vivax
malaria in Bikaner (western India). Patients exhibited cere-
bral malaria, renal failure, circulatory collapse, severe ane-
mia, hemoglobinurea, abnormal bleeding, acute respiratory
distress syndrome, and jaundice. Peripheral blood
microscopy, parasite antigen–based assays, and parasite
18s rRNA gene–based polymerase chain reaction showed
the presence of P. vivax and absence of P. falciparum.
P
lasmodium vivax malaria is prevalent in many regions
of the world. It accounts for more than half of all
malaria cases in Asia and Latin America. Despite the high
prevalence of disease caused by this parasite, research into
its effects has lagged disproportionately (1). 
Organ dysfunction seen in P. falciparum malaria is not
seen in P. vivax infections. Thus, severe malaria is report-
ed with P. falciparum but not with P. vivax infection. If a
patient with P. vivax exhibits severe malaria, the infection
is presumed to be mixed. When patients have a mixed
infection, P. vivax may lessen the effect of P. falciparum
and cause the disease to be less severe. Luxemburger et al.
observed that severe malaria is 4.2 times less common in
patients with mixed P. falciparum and P. vivax infections
than in those with P. falciparum alone (2).
The Study
During the post-rainy season epidemic of malaria from
August to December 2003, many persons along the
India–Pakistan border had severe malaria caused by P.
vivax. During the last few outbreaks, we made similar
observations, but in 2003 the number of cases was compar-
atively higher. Clinically severe cases and complications
of malaria are commonly due to P. falciparum and not to P.
vivax. Beg et al. reported a patient from Pakistan with cen-
tral nervous system (CNS) involvement with P. vivax, in
which the diagnosis was confirmed by polymerase chain
reaction (PCR) studies. Beg et al. reviewed the P. vivax
cases with CNS involvement reported before 2002; how-
ever, most were diagnosed by examination of peripheral
blood films (PBF) (3). 
We searched available literature and could find only
isolated reports of severe P. vivax malaria with cerebral
malaria, thrombocytopenia, disseminated intravascular
coagulation (DIC), acute respiratory distress syndrome
(ARDS), and renal involvement caused by P. vivax. In
most cases, the diagnosis was made by PBF examination
without molecular diagnostic confirmation, thus allowing
for potential errors in species diagnosis (4–13). Although
detection of P. vivax in PBF is the standard, its presence
does not rule out undetected mixed infection. To rule out
this possibility, all the patients received a thorough diag-
nostic evaluation, which included PBF examination, a
rapid diagnostic test for malaria (OptiMAL test, DiaMed
AG, Switzerland, which is based on detecting specific
Plasmodium LDH antigen by using monoclonal antibody
directed against isoforms of the enzyme), and PCR. Our
findings are shown in Tables 1 and 2. 
All patients were admitted to an intensive care ward
dedicated to malaria control. Clinical, biochemical, and
radiologic examinations were conducted to establish the
diagnosis. Severe malaria was categorized and a treatment
regimen of intravenous quinine was instituted according to
World Health Organization guidelines (14). Formal
approval of the hospital’s ethical committee and consent of
the patients were obtained for further studies.
The PCR studies were targeted against the 18S rRNA
gene of the parasite and were based on conditions reported
earlier (15) utilizing 1 genus-specific 5′ primer and 2
species-specific 3′ primers in the same reaction cocktail.
Some of the primer sequences were modified for this
study: 1) 5′ATCAGCTTTTGATGTTAGGGT ATT 3′–
genus specific, 2) 5′ TAACAAGGACTTCCAAGC–P.
vivax specific, and 3) 5′GCTCAAAGATACAAATATA-
AGC 3′–P. falciparum specific (Figure). Our PCR results
in each sample ruled out the possibility of coinfection with
P. falciparum. Each sample was subjected to a minimum of
4 rounds of PCR with varying template amounts to elimi-
nate the possibility of overlooking P. falciparum coinfec-
tion. In this report, we have not included 2 samples that
showed P. vivax infection in PBF examination but showed
evidence of mixed infection in PCR examination. The
result of PCR analysis of 1 sample is shown in lane 8 of the
Figure.
Conclusions
The essential pathologic feature of severe malaria is
sequestration of erythrocytes that contain mature forms of
the parasite in the deep vascular beds of vital organs, thus
producing cerebral malaria, renal failure, hepatic dysfunc-
tion, or ARDS. However, severe anemia and thrombocy-
topenia that causes bleeding diathesis is produced by
hemolysis, reduced cell deformity of parasitized and non-
parasitized erythrocytes, increased splenic clearance,
reduction of platelet survival, decreased platelet produc-
tion, and increased splenic uptake of platelets, and can be
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ical data from these patients strongly indicate that P. vivax
can cause both sequestration-related and nonsequestration-
related complications of severe malaria, including cerebral
malaria, renal failure, circulatory collapse, severe anemia,
hemoglobinurea, abnormal bleeding, ARDS, and jaundice,
all of which are commonly associated with P. falciparum
infections. None of the patients described in this study had
evidence of P. falciparum infection at the level of antigen
(parasite LDH) and 18S rRNA–based PCR test, apart from
PBF examination.
This is the first detailed report of severe P. vivax malar-
ia. We cannot comment on a pathogenic mechanism caus-
ing multiple organ dysfunction and the characteristics of
host-parasite interrelationship responsible for it. Adetailed
prospective study is required to address these issues.
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Figure. Polymerase chain reaction analysis of patient samples:
lane Pf = positive control showing Plasmodium falciparum band at
position 1,400 bp; lanes 1–7 and 9–12 = P. vivax–positive samples
showing band at ≈500 bp; (lanes 1–7 correspond to cases 1–7,
and lanes 9–12 correspond to patients 8–11 numbered in Tables 1
and 2.); lane 8 = sample showing bands at ≈1,400 bp and 500 bp,
indicating mixed infection; lane 13 = negative control, normal
human DNA; lane 1kb = 1kb DNA ladder mix (MBI Fermentas,
SM#0331)
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